FOXA2 and metabolic disease: The molecular mechanism linking lipid-based abnormalities to metabolic disorders has been shown to be associated with insulin-mediated FOXA2 repression in obese and high-fat diet states, leading to elevated triglycerides and reduced plasma high-density lipoprotein (HDL) levels [28, 29].